by 
Implantable Insulin Pumps Market Key Takeaways
- In terms of revenue, the global implantable insulin pumps market was valued at USD 5.24 billion in 2024.
- It is projected to reach USD 14.27 billion by 2034.
- The market is expected to grow at a CAGR of 10.54% from 2025 to 2034.
- North America dominated the implantable insulin pumps market with the largest share of 44.7% in 2024.
- Asia Pacific is expected to grow at the highest CAGR from 2025 to 2034.
- By pump type, the programmable implantable pumps segment led the market with a 52.4% share in 2024 and is expected to sustain its position in the coming years.
- By reservoir size, the medium volume (10-20 ml) segment captured the biggest market share of 39.1% in 2024.
- By reservoir size, the large volume (>20 ml) segment is expected to grow at a significant CAGR over the projected period.
- By delivery mode, the combined basal-bolus delivery segment contributed the highest market share of 46.8% in 2024.
- By delivery mode, the continuous basal delivery segment is anticipated to grow at a significant CAGR from 2025 to 2034.
- By end user, the hospitals segment held the biggest market share of 41.3% in 2024.
- By end user, the homecare segment is expected to grow at the fastest CAGR from 2025 to 2034.
- By age group, the adults (18–64 years) segment generated the major market share of 54.2% in 2024.
- By age group, the pediatrics segment (≤17 years) is projected to grow at a significant CAGR between 2025 and 2034.
- By indication, the type 1 diabetes mellitus (T1DM) segment accounted for significant market share of 62.9% in 2024.
- By indication, the type 2 diabetes mellitus (T2DM) segment is expected to experience rapid growth during the forecast period.
- By distribution channel, the direct hospital procurement segment held a remarkeble market share of 47.5% in 2024.
- By distribution channel, the online pharmacy segment is expected to grow at a significant CAGR from 2025 to 2034.
The Role of AI in Advancing the Implantable Insulin Pumps Market
Artificial intelligence (AI) is revolutionizing the implantable insulin pumps market by powering the development of advanced automated insulin delivery (AID) systems. These AI-driven systems integrate data from continuous glucose monitors (CGMs) with insulin pumps to predict glucose fluctuations and automatically adjust insulin doses in real-time. By analyzing large volumes of patient data with high accuracy, AI can help prevent hypoglycemic and hyperglycemic episodes, reduce the burden of diabetes management, and improve overall patient outcomes. This level of proactive, data-informed insulin regulation marks a significant step forward in personalized diabetes care.
Market Overview
The implantable insulin pumps market encompasses the global industry involved in the design, development, manufacturing, and commercialization of surgically implanted devices that deliver continuous, controlled doses of insulin directly into the peritoneal cavity. These pumps are primarily used for patients with Type 1 Diabetes Mellitus (T1DM) and aim to provide improved glycemic control by minimizing glucose fluctuations. By eliminating the need for frequent subcutaneous injections or reliance on external pumps, implantable insulin pumps enhance patient comfort and adherence. Compared to external devices, they offer reduced visibility, lower infection risk, and more consistent long-term performance. Market growth is driven by the increasing global prevalence of diabetes and ongoing technological advancements in insulin delivery systems.
Key Trends in the Implantable Insulin Pumps Market
- Growing Awareness of Insulin Pump Therapy: Awareness is rising among both patients and healthcare professionals regarding the benefits of insulin pump therapy. These include improved glycemic control, greater lifestyle flexibility, reduced diabetes-related complications, and enhanced convenience. As understanding deepens, adoption rates of implantable insulin pumps are steadily increasing.
- Emphasis on Personalized Medicine and Data-Driven Therapeutics: The integration of connected insulin pumps with continuous glucose monitoring (CGM) systems generates real-time data that enables personalized treatment strategies. Advanced analytics can predict blood glucose trends, tailor insulin dosing, and detect early warning signs, fostering a more proactive and preventive approach to diabetes management.
- Rising Patient Preference for Implantable Solutions: Many individuals with diabetes are opting for implantable insulin pumps over multiple daily injections or external devices. The precision, discretion, and reduced maintenance of implantable systems contribute to improved clinical outcomes and enhanced patient satisfaction.
- Technological Advancements and Smart Delivery Systems: Innovations such as closed-loop systems—often referred to as artificial pancreases—and the integration of AI and machine learning into insulin delivery are revolutionizing the market. These technologies significantly reduce manual input, automate insulin regulation, and lower the risks of hypo- and hyperglycemia. The development of intelligent, automated delivery systems continues to drive market growth and improve patient care.
Opportunity
Advancing Automated Insulin Delivery Systems
A major growth opportunity in the implantable insulin pumps market is the continued development of automated insulin delivery (AID) systems, also known as closed-loop systems. These innovative solutions integrate continuous glucose monitors (CGMs), implantable insulin pumps, and intelligent algorithms to automatically adjust insulin dosing in real time. By significantly reducing the need for manual intervention, AID systems enhance glycemic control and simplify day-to-day diabetes management. Ongoing advancements in device miniaturization, user-friendliness, and affordability are making these technologies more accessible, widening their appeal and adoption among individuals with diabetes.
Recent Developments
- In April 2025, Medtronic plc announced that it had applied for FDA clearance for an interoperable insulin pump that integrates with Abbott’s continuous glucose monitoring (CGM) platform, thereby enhancing treatment options for people with diabetes. The application includes submissions for the MiniMed™ 780G as an ACE pump and the SmartGuard™ algorithm as an automated glycemic controller. Medtronic’s partnership with Abbott aims to deliver innovative solutions for diabetes management.
- In June 2024, Arecor Therapeutics partnered with Medtronic to develop a high-concentration, thermostable insulin formulation for next-generation implantable pumps. Using Arecor’s Arestat™ technology, this new formulation seeks to improve treatment options for patients who require stable insulin, potentially lowering healthcare costs and enhancing care quality. This collaboration aims to transform treatment for a vulnerable patient population and expresses hope for future partnerships that will further enhance the benefits of next-generation devices.
- In September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the FDA cleared the next-generation Eversense 365 system for adults with Type 1 and Type 2 diabetes. This new continuous glucose monitoring (CGM) system is the world’s first one-year sensor, improving sensor longevity, connectivity, and accuracy to help patients maintain desired glucose levels and lower A1c, marking a significant step forward in diabetes management.
- In March 2024, the Twiist AID system became the first insulin pump integrated with Tidepool Loop, providing precise microdosing and customizable bolusing based on food types. Developed by Sequel Med Tech, this innovative system measures volume and flow for personalized insulin dosing. It is also the first FDA-approved insulin pump that can be controlled via Apple Watch. Dr. Natalie Bellini praised this groundbreaking option for diabetes management.
Implantable Insulin Pumps Market Key Players
- Medtronic plc
- Insulet Corporation
- Tandem Diabetes Care Inc.
- Roche Diabetes Care
- SOOIL Development Co., Ltd.
- Debiotech SA
- Beta Bionics
- Valeritas Inc.
- Ypsomed Holding AG
- CeQur SA
- Eli Lilly and Company (Automated Delivery Division)
- Bigfoot Biomedical
- Senseonics Holdings Inc.
- ViaCyte Inc.
- Dompe Farmaceutici SpA
- Terumo Corporation
- Delfu Medical
- ViCentra B.V.
- Eoflow Co., Ltd.
- Rani Therapeutics
